The concern of generic rivalry has repeatedly loomed above copyright’s famous drug, Sildenafil, raising questions about the future of connected medicinal investments. While initial periods saw significant gains, the intellectual property lapse has allowed the way for discounted substitutes, possibly reducing earnings and posing a real hazard for